

JACC REVIEW TOPIC OF THE WEEK

PCI and CABG for Treating Stable Coronary Artery Disease



JACC Review Topic of the Week

Torsten Doenst, MD, PhD,^a Axel Haverich, MD, PhD,^b Patrick Serruys, MD, PhD,^c Robert O. Bonow, MD, MS,^d Pieter Kappetein, MD, PhD,^e Volkmar Falk, MD, PhD,^f Eric Velazquez, MD,^g Anno Diegeler, MD, PhD,^h Holger Sigusch, MDⁱ

ABSTRACT

Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are considered revascularization procedures, but only CABG can prolong life in stable coronary artery disease. Thus, PCI and CABG mechanisms may differ. Viability and/or ischemia detection to guide revascularization have been unable to accurately predict treatment effects of CABG or PCI, questioning a revascularization mechanism for improving survival. By contrast, preventing myocardial infarction may save lives. However, the majority of infarcts are generated by non-flow-limiting stenoses, but PCI is solely focused on treating flow-limiting lesions. Thus, PCI cannot be expected to significantly limit new infarcts, but CABG may do so through providing flow distal to vessel occlusions. All comparisons of CABG to PCI or medical therapy that demonstrate survival effects with CABG also demonstrate infarct reduction. Thus, CABG may differ from PCI by providing "surgical collateralization," prolonging life by preventing myocardial infarctions. The evidence is reviewed here. (J Am Coll Cardiol 2019;73:964-76) © 2019 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Coronary artery disease (CAD) causes angina pectoris, myocardial infarction, and ischemic heart failure and thereby contributes significantly to cardiovascular disease being the leading cause of death worldwide (1). CAD is characterized by the development of atherosclerotic plaques inside the coronary vessel wall that stenose the vessel (causing ischemia) or that can rupture, which through thrombotic vessel occlusion represents the major mechanism for acute myocardial infarction (AMI)

(2). Myocardial infarction or chronic ischemia through severely stenotic CAD may lead to heart failure and/or death (2). Treatment of CAD is therefore aimed at alleviating angina symptoms and preventing AMI or premature death (1). Next to medical therapy (MED), mainly consisting of angina control and prevention or reversal of plaque progression, 2 (more or less) invasive strategies are available, aimed at re-establishing adequate blood supply to undersupplied myocardial territories due to severe coronary stenosis



Listen to this manuscript's
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.

From the ^aDepartment of Cardiothoracic Surgery, University Hospital Jena, Friedrich Schiller University of Jena, Jena, Germany; ^bDepartment of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; ^cNational Heart and Lung Institute, Imperial College London, London, United Kingdom; ^dDepartment of Medicine-Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^eDepartment of Cardio-Thoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; ^fDepartment of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany; ^gDepartment of Internal Medicine, Yale School of Medicine, New Haven, Connecticut; ^hDepartment of Cardiac Surgery, Heart Center Bad Neustadt, Bad Neustadt, Germany; and the ⁱDepartment of Cardiology, Heinrich-Braun-Hospital, Zwickau, Germany. Dr. Kappetein is an employee of Medtronic. Dr. Falk has received research or educational grants and/or fees for lecturing or consulting from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, Berlin Heart, and Novartis Pharma. Dr. Velazquez has been a consultant to Novartis, Amgen, and Philips; and has received research funding from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received September 14, 2018; revised manuscript received November 9, 2018, accepted November 26, 2018.

or vessel occlusion, that is, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) (1).

A plethora of trials have compared the 2 (or 3, if MED is included) treatment strategies for their ability to achieve the aforementioned treatment goals (Table 1). Several publications, comments, and reviews have addressed these comparisons and have come to 2 main (and possibly sobering) conclusions (Table 1) (3–21). First, PCI in stable CAD, independent of stent type used, has thus far failed to report an improvement in survival or a significant reduction in new myocardial infarctions (16). Second, improved survival and reductions in new myocardial infarctions has been consistently demonstrated for CABG in stable CAD, but this effect is not always detectable and seems to be dependent on the severity of CAD (15) (Table 1) and possibly the presence of diabetes mellitus (7,22,23).

These findings are somewhat surprising because both procedures have always been considered revascularization treatments (1) and should therefore have similar effects. However, the majority of AMIs are not caused by flow-limiting lesions (24–38), but our current revascularization strategy focusses more and more on treating only flow-limiting stenoses (38,39). In addition, the majority of deaths in this patient population are due to cardiac reasons, mainly AMI (22,23,40,41). Thus, protection against infarction may be an underappreciated mechanism although it had been suggested previously (22,42). Because native collateralization protects from infarction of acute vessel occlusion (24–28,32), CABG may do the same surgically.

We searched the published reports and looked for possible explanations of the difference in clinical impact of CABG and PCI. We present here a collection of (circumstantial) evidence to make the case that CABG, although a revascularization treatment and thereby comparable to PCI in treating angina, is able to provide a survival benefit by protecting against new myocardial infarctions (i.e., creating “surgical collateralization”) (Central Illustration).

REVIEWING THE EVIDENCE

PATHOPHYSIOLOGY OF CAD. CAD is generally caused by atherosclerotic plaque formation. Plaques form inside the vessel and lead to varying degrees of lumen obstruction. Such a stenosis is considered to be hemodynamically relevant once the degree exceeds 70% (43). Since fractional flow-reserve (FFR) has emerged, the assessment of severity degree may differ compared with conventional eyeball

assessment. However, the number of stenoses determined as flow-limiting has not increased (31,39,44). Hemodynamically relevant flow obstructions can cause ischemia in the distal myocardium. The resulting symptoms are ischemic pain (classically angina pectoris) and/or dyspnea as expression of ischemic pump failure. (Of note, ischemic symptoms may appear in the absence of significant epicardial disease, but this is not the topic of this review). In the setting of epicardial disease with patients amenable for CABG or PCI, non-flow-limiting stenoses are generally asymptomatic. However, rupture of these plaques, often followed by thrombotic vessel occlusion, represents the main mechanism of myocardial infarction (1,24). Importantly, plaques can rupture without causing an infarct. In this case, the thrombus may either not fully occlude the vessel or collateral flow may protect the myocardium from infarction (45). The latter mechanism explains the relatively large number of coronary occlusions in clinical practice. In addition, CAD is a disease that migrates from proximal parts of the vessel system distally, and the vast majority of plaque burden is found in the first few centimeters of the coronary vessels (42,46).

Figure 1A shows the quantitative distribution of CAD in the human coronary system dependent on the degree of stenosis and at which rate it causes vessel occlusions within 5 years. The data come from a summary of a series of angiographic and/or pathological studies (25–28,32). Figure 1B demonstrates the percentage at which the different degrees of stenoses are the cause of myocardial infarction. It is evident that the higher the degree of stenosis, the greater the risk for this stenosis to occlude or cause an infarct. However, because the lesions with lower degrees of stenosis by far outnumber those with higher stenotic degrees, the majority of myocardial infarctions in real life are caused by stenoses with a stenotic degree of <70% (i.e., most likely non-flow-limiting lesions). This finding is illustrated in Figure 1C. It is an important recognition with respect to the expectations of current treatment strategies because the figure shows that the vast majority of new myocardial infarctions are caused by non-flow-limiting stenoses. Because PCI (more often supported by FFR or intravascular ultrasound nowadays [38]) focuses on treatment of primarily flow-limiting stenoses (38), one may ask, why do we actually expect a significant reduction of myocardial infarctions by PCI?

ABBREVIATIONS AND ACRONYMS

AMI	= acute myocardial infarction
CABG	= coronary artery bypass grafting
CAD	= coronary artery disease
CI	= confidence interval
CT	= computed tomography
EES	= everolimus-eluting-stent
FFR	= fractional flow reserve
MED	= medical therapy
PCI	= percutaneous coronary intervention
R-ZES	= Resolute zotarolimus-eluting-stent
STEMI	= ST-segment elevation myocardial infarction

TABLE 1 Summary Information for All Current Prospective Randomized Controlled Trials Comparing CABG and PCI

Trial Name Follow-Up Period (Year) (Ref. #)	Primary Endpoint	Degree of CAD	Mortality PCI vs. CABG (%)	New MI PCI vs. CABG (%)	Cardiac Death PCI vs. CABG (%)
ARTS 1 yr (2005) (3) 3 yrs (2005) (3) 5 yrs (2005) (3)	Freedom from MACCE	Multivessel disease (>60% 2-vessel, >30% 3-vessel)	2.5 vs. 2.8 3.7 vs. 4.6 8.0 vs. 7.6	6.0 vs. 4.6 7.3 vs. 5.7 8.5 vs. 6.6	n. a. n. a. n. a.
BEST 2 yrs (2015) (4)	Composite of death, MI, or target- vessel revascularization at 2 yrs	Multivessel disease (>70% 3-vessel)	6.6 vs. 5.0	4.8 vs. 2.7	4.1 vs. 3.7
CARDia 1 yr (2010) (5)	Composite of all-cause mortality, MI and stroke	Symptomatic multivessel disease (>60% 3-vessel)	3.2 vs. 3.2	9.8 vs. 5.7	n. a.
EXCEL 3 yrs (2016) (6)	Composite of death from all cause, stroke, or MI	Left main coronary artery stenosis of at least 70%	8.2 vs. 5.9	8.0 vs. 8.3	4.4 vs. 3.7
FREEDOM 2 yrs (2012) (7) 5 yrs (2012) (7)	Composite of all-cause mortality, nonfatal MI, or stroke	Multivessel disease (>80% 3-vessel)	6.7 vs. 6.3 16.3 vs. 10.9	6.7 vs. 4.7 13.9 vs. 6.0	0.9 vs. 1.3 10.9 vs. 6.8
MASS II 5 yrs (2007) (8)	Total mortality, Q-wave MI or refractory angina requiring revascularization	Multivessel disease (>40% 2-vessel, >55% 3-vessel)	15.5 vs. 12.8	11.2 vs. 8.3	11.6 vs. 7.9
NOBLE 1 yr (2016) (9) 5 yrs (2016) (9)	Freedom from MACCE at 5 yrs	Left main coronary artery disease of at least 50%	2.0 vs. 3.0 12.0 vs. 9.0	2.0 vs. 1.0 7.0 vs. 2.0	1.0 vs. 2.0 3.0 vs. 3.0
PRECOMBAT 5 yrs (2015) (10)	Freedom from MACCE	Unprotected left main coronary artery stenosis	5.7 vs. 7.9	2.0 vs. 1.7	n. a.
SoS 2 yrs (2002) (11)	Comparison of the rates of repeat revascularization	Multivessel disease (>50% 2-vessel, >35% 3-vessel)	5.0 vs. 2.0	4.0 vs. 7.0	n. a.
SYNTAX 1 yr (2009) (12) 3 yrs (2011) (13) 5 yrs (2014) (14)	Noninferiority of major adverse cardiac and cerebral events	3-vessel disease	4.4 vs. 3.5 8.6 vs. 6.7 14.6 vs. 9.2	4.8 vs. 3.3 7.1 vs. 3.6 10.6 vs. 3.3	3.7 vs. 3.1 6.0 vs. 3.6 9.2 vs. 4.0

ARTS = Arterial Revascularization Therapies Study; BEST = Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease study; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CARDia = Coronary Artery Revascularization in Diabetes; EXCEL = EXCEL Clinical Trial; FREEDOM = Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes study; MACCE = major adverse cardiac and cerebrovascular events; MASS II = Medicine, Angioplasty, or Surgery Study; MI = myocardial infarction; n. a. = not available; NOBLE = PCI vs. CABG in the Treatment of Unprotected Left Main Stenosis study; PCI = percutaneous coronary intervention; PRECOMBAT = Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease study; SoS = Stent or Surgery Trial; SYNTAX = TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries study.

RISKS AND CAUSES OF DEATH IN STABLE CAD.


Every invasive treatment method carries a certain risk. For proper decision-making, the risks of the natural cause of the disease (or in case of CAD, the risks associated with CAD under optimal medical treatment) need to be known.

Figure 2 shows an image modified from the current European Society of Cardiology guidelines on myocardial revascularization, illustrating the risk of dying under optimal MED within 1 year, dependent on the degree of CAD. Accordingly, patients with single-vessel disease have a 1.4% yearly risk of dying from this problem, whereas it increases to >8%

per year in patients with triple-vessel disease including the left main artery. It is currently generally accepted that the main causes of death in these patients are of cardiac origin (1,40), specifically in patients with diabetes mellitus (7,22,23,41).

Thus, myocardial infarction appears to be a major mechanism for death from CAD. Treatments reducing the occurrence of myocardial infarction should therefore potentially be able to reduce mortality from CAD, but the “visibility” of this effect is related to the inherent risk of the treatment itself. Statistically speaking, the detectability of a treatment impact on survival depends on 3 factors: periprocedural

CENTRAL ILLUSTRATION Infarct Prevention Through Bypass Grafting



Doenst, T. et al. *J Am Coll Cardiol.* 2019;73(8):964–76.


Schematic illustration of mechanistic differences between percutaneous coronary intervention and coronary artery bypass grafting (CABG). Although both stents and bypass grafts provide revascularization to vascular territories affected by flow-limiting stenoses, only CABG also provides protection against vessel occlusions (i.e., myocardial infarctions) from non-flow-limiting stenoses, because the majority of bypass graft insertions are performed distal to the plaque location.

mortality, length of the observation period, and natural risk of the disease. Thus, periprocedural risks and treatment effects need to be evaluated against the duration of the observation period, which may explain several of the concurrent possibly contradictory findings from current CABG versus PCI trials.

The STICH (Surgical Treatment for Ischemic Heart Failure) trial is a perfect example for this statement. The trial compared CABG to optimal MED in patients with ischemic heart failure. There was no statistically significant survival improvement at the 5-year endpoint (47) but there was at 10 years (resulting in an 18 months longer average survival in the operated patients) (48). Another trial may be the SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries) study, in which patients with triple-vessel disease either received PCI or CABG. Figure 3 shows the cumulative event rate at 5 years for the 2 patient groups according to their SYNTAX score. The figure illustrates that CABG is superior to PCI if the SYNTAX score is high, and PCI is comparable to CABG if the SYNTAX score is low. Yet, extrapolating the curves to 10 years may possibly also show superiority for CABG. However, despite the absence of long-term follow-up

in most trials, reviewing the evidence from concurrent trials is already revealing.

EVIDENCE FROM TRIALS. A plethora of investigations has addressed the potential of PCI to improve survival and to reduce myocardial infarctions in patients with stable CAD compared with MED alone (1,16). The sobering finding was that PCI has consistently failed to improve survival or to reduce new myocardial infarction in stable CAD. A recent network meta-analysis suggested a survival benefit of new-generation drug-eluting stents over MED, giving a rate ratio of 0.75 (95% confidence interval [CI]: 0.59 to 0.96) for everolimus-eluting stents (EES) and of 0.65 (95% CI: 0.42 to 1.00) for Resolute zotarolimus-eluting stents (R-ZES) (Medtronic, Dublin, Ireland) (49). However, the actual trial comparing EES to MED (39) demonstrated equal rates of all-cause mortality ($p = 0.31$), and a comparison of R-ZES with MED has never been conducted. In addition, the recent NORSTENT (Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis) demonstrates equal survival rates for patients with exactly this everolimus-eluting stent compared with concurrent bare-metal stents (50). By contrast, comparisons of PCI to CABG have consistently

FIGURE 1 Coronary Occlusion/MI as Function of CAD Stenosis Severity

Bar graphs showing stenosis severity and associated risk of coronary occlusion and myocardial infarction (MI) as evaluated by serial angiographic examination. The more stenotic an individual coronary segment is at baseline, the more frequently it progresses to occlusion (**A**) and/or gives rise to infarction (**B**). Because less-obstructive plaques by far outnumber severely obstructive plaques, most occlusions and infarctions result from progression of the less-obstructive plaques. Thus, myocardial infarction evolves most frequently from plaques that are only mildly to moderately obstructive (**C**). Bar graphs are constructed from data published by (**A**) Alderman et al. (26); (**B**) Nobuyoshi et al. (32); and (**C**) Ambrose et al. (27), Little et al. (25), Nobuyoshi et al. (32), and Giroud et al. (28). CAD = coronary artery disease.

demonstrated potential superiority of CABG, independent of stent type used (4,29,41).

In addition, all trials comparing PCI and CABG have been performed in patients without previous PCI. PCI per se may disturb the coronaries' inherent vasomotor function, possibly causing adverse events (51), and increase perioperative risk if CABG is needed (52).

Table 1 displays a summary of all important prospective randomized controlled trials having compared CABG and PCI in the last 15 years. Note that 77% of trials suggest a better survival with CABG. Although the effects of CABG appear to be most prevalent in patients with diabetes mellitus (1,7,23), the therapeutic impact may be similar in patient populations with lower percentages of diabetic patients (14). There are only a few investigations comparing coronary bypass grafting to MED alone without including coronary interventions (26,35). The STICH trial is the most recent and largest trial of such kind. As already mentioned, CABG provided a significant survival benefit over MED alone after 10 years. Importantly, the treatment effect could not be predicted by assessing pre-operative viability (53) or the presence of ischemia (54).


VIABILITY OR ISCHEMIA TESTING AND ITS EFFECT ON OUTCOME AFTER PCI AND CABG. There is an ongoing debate whether diagnostic tools detecting ischemia and/or viability/scar should be used for decision-making in PCI and CABG. It is recommended that for any revascularization strategy, the presence of viable, but ischemic, myocardium is determined (1). Although the rationale is convincing and the effect of this approach can be witnessed by the disappearance or alleviation of ischemia symptoms, the ability of this strategy to improve survival or reduce new myocardial infarctions has thus far not been demonstrated in a prospective randomized trial (1). The guidelines currently suggest that revascularization is useful for mortality reduction if the ischemic territory is >10%. This suggestion is based on 2 publications on nearly the same patient population (55,56) that evaluated the impact of ischemia and scar assessment on the therapeutic benefit from myocardial revascularization. Although the data are convincing, the authors compared a large group of medically treated patients ($n \approx 12,000$) to those having received revascularization ($n = 1,226$). However, roughly 40% of revascularized patients received CABG and the other part received PCI. The papers do not differentiate the treatments any further. The authors show that revascularization lowered mortality rates in patients with ischemic territories on single-photon emission computed tomography

imaging of >10%. They also demonstrate that mortality with revascularization may even be higher with small ischemic territories (<5%). These data were taken to conclude, that revascularization of significantly ischemic myocardium improves survival (1). However, our present rationale would require differentiating the data further into outcomes of patients having undergone CABG or PCI. Although the overall mortality rate for both invasive strategies were similar in these reports, it is conceivable that CABG was primarily performed in patients with more severe CAD (i.e., more triple-vessel disease and therefore more ischemic territories and natural risk) and PCI was primarily performed in those with less severe CAD patients (i.e., single- and double-vessel disease, subsequently smaller ischemic territories, and lower natural risk) (Figure 4A). Thus, it is well conceivable that the outcomes may not be dependent on the degree of ischemic territory, but instead on the type of revascularization. The currently ongoing ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches; NCT01471522) will hopefully clarify whether treating ischemia in stable CAD affects survival. However, the trial also combines PCI and CABG as revascularization for the comparison to MED.

The evidence from the STICH trial demonstrates that both viability testing and ischemia detection serve well to predict prognosis (i.e., patients with viability and/or ischemia live longer than those without it), but they are not helpful for decision-making for the performance of CABG (Figure 4B). In other words, CABG still appears to prolong life in patients without acutely ischemic or viable myocardium.

The STICH findings and the methodological concerns regarding the main evidence currently applied for predicting the revascularization effect on mortality suggest that revascularization may not be a main mechanism for mortality reduction. Thus, the finding of infarct reductions and reduced cardiac deaths with CABG may therefore represent a known (22,42), but underappreciated, mechanism to explain the survival impact (14). Thus, CABG may be considered as infarct-reducing treatment by bypassing diseased coronary territories (i.e., providing “surgical collateralization” in addition to revascularization).


It is important to state in this context again that myocardial infarction is a major, but not the only, cause of cardiovascular mortality. Assessing the data presented here suggests that CABG may reduce infarcts and cardiovascular mortality up to a maximum of 50% (average 30%) (Table 1, Figure 5). Thus, there is



plenty of room for other causes of cardiovascular mortality and mechanisms of cardiovascular protection (57). However, in light of the mechanistic differences between CABG and PCI, CABG’s ability to prevent new infarctions deserves further examination.

INFARCT REDUCTION AS POTENTIAL CAUSE FOR IMPROVING SURVIVAL WITH CABG. Table 1 also displays a summary for rates of nonlethal myocardial infarctions and cardiac deaths for the aforementioned trials. It is striking to note that the overall lower mortality with CABG from these trials was accompanied also by reductions in nonlethal myocardial infarction and cardiac death. Figure 5 shows a graphic illustration of the difference in mortality between CABG and PCI of these trials as a function of the difference in nonlethal myocardial infarction versus all-cause mortality (Figure 5A) or cardiac death (Figure 5B). The highly significant correlation is striking. Although this association does not prove that CABG’s ability to prolong life is caused by its ability to reduce infarctions, the notion, however, is strong and is supported further by the following circumstantial evidence.

FIGURE 3 Outcome of PCI Versus CABG by SYNTAX Score



Cumulative event rates for PCI and CABG according to the 3 SYNTAX score groups from the SYNTAX trial. Note that the event rates increase with PCI with increasing SYNTAX scores and are stable with CABG. Note also that in the low SYNTAX group (0 to 22, left) the curves cross between 12 and 24 months. Reproduced with permission from Head et al. (14). CABG = coronary artery bypass grafting; KM = Kaplan-Meier; PCI = percutaneous coronary intervention; SYNTAX = TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries study.


Mushtaq et al. (58) have addressed the impact of atherosclerotic burden on prognosis in patients with suspected CAD. They evaluated the Leaman score to quantify plaque load determined by computed tomography (CT) and found that patients with a high plaque load have more cardiac events than those low plaque load. Note in Figure 6A that patients with large atherosclerotic burden (CT Leaman score >5) and non-flow-limiting coronary stenosis (CAD $<50\%$) have the same event rate as those patients with significantly flow-limiting stenoses. Thus, plaque load seems to be an important contributor to CAD morbidity and mortality, which underscores the discussion earlier in the text on infarct-inducing stenoses (Figure 2).

Two other investigations have addressed the spatial distribution of coronary vessel occlusions from CAD (46) and the site of bypass graft insertion (42). The vast majority of infarct-inducing vessel occlusions occur in the proximal one-third of the 3 main vessels (46), and the majority of bypass grafts are placed distal to a potential vessel occlusion from CAD (42) (Figure 6B). These studies fully support our main conclusion by stating that coronary bypass grafts may protect against infarction by covering anatomic zones at risk for ST-segment elevation myocardial infarction.

Considering these findings, it is interesting to re-review the main findings of the SYNTAX trial. Figure 3 also shows that dependent on SYNTAX score, the event rate continuously increases in the PCI groups but not in the CABG groups. Thus, the severity of coronary artery disease only appears to be a risk factor for PCI. Because the main mechanism of death is cardiac (7,23,40,41) and perioperative risk appears similar, independent of the SYNTAX score, this finding also suggests that infarct reduction is the main reason for the difference in all-cause mortality.


This line of reasoning is further supported by studies demonstrating improved survival of CABG compared with PCI in patients with dialysis-dependent renal failure (30,59). Although it is undebated that renal failure increases perioperative risk, long-term survival is still consistently better with CABG (36). Importantly, myocardial infarction and cardiac death are the main causes of death in patients with severe renal failure (30,36,59).

Finally, our argument is even supported by the aforementioned network meta-analysis that suggested a survival benefit for the new drug-eluting stents through sophisticated statistics (49), without direct evidence (39). However controversial this finding may be, it is interesting to note that the



demonstration of a possible survival impact through low-risk ratios for drug-eluting stents versus MED is directly related to similarly low-risk ratios for infarct reduction (risk ratios, 95% CI for all cause-mortality: EES vs. MED: 0.75; 0.59 to 0.96, R-ZES vs. MED: 0.65; 0.42 to 1.00; for myocardial infarction: EES vs. MED: 0.75; 0.55 to 1.01, R-ZES vs. MED: 0.82; 0.52 to 1.26) (49).

“IDEAL STENT” VERSUS “IDEAL BYPASS GRAFT” AND A “REAL-WORLD-SOLUTION INCLUDING MED”. Taking all the aforementioned considerations into account, the ideal stent would be free of thrombosis, not require re-revascularization, and maintain vasomotor/vascular function. Then, in theory, all plaques could be stented, and a reduction of infarcts and improved survival could be expected. The real



world of PCI for stable CAD lacks a measurable impact on survival or infarction. That statement is true for the continuously renewed drug-eluting stents (14,17,18,38,39,50), as well as for the new bioabsorbable stents (37,60).


In analogy, the ideal bypass graft would not occlude. CAD would be treated by grafting all areas with CAD, and the treatment effect would be larger than it already is. The real world, however, shows

occlusion rates of up to 25% at 1 year (61), and even arterial grafts occlude at a rate that appears to be dependent on the degree of collateral flow (62). If the current trend to graft target vessels guided by FFR measurements (34,63) is continued, the impact of CABG to reduce survival may even be reduced because fewer target vessels are likely to be grafted.

In addition, the impact of MED and primary prevention measures may not be underestimated. That includes MED to control symptoms as well as strategies to prevent or reverse plaque progression (64). The recently published SCOT HEART trial (Scottish Computed Tomography of the HEART) (57) is well suited to illustrate the magnitude of these measures on cardiac events. The pure knowledge about the extent of CAD (based on a CT coronary angiogram) allowed the treating physicians to achieve around 40% reduction in infarcts. This reduction must have been due to primary prevention measures, because the fraction of patients having received invasive diagnosis and therapy has been identical. This finding, in concert with the illustrated inability of ischemia and scar detection methods to predict revascularization outcomes, underscores our conclusion that the reported difference in survival between CABG and PCI must be due to effects beyond revascularization. It also leads to the need of optimal MED in both PCI and CABG patients, which has been underscored by the most recent European Society of Cardiology revascularization guidelines (1).

Because in real life, the conditions are rarely ideal, individualization based on obeying current evidence may have the potential to achieve the best patient outcome. Such individualized decision-making requires a true heart team including a noninterventional, nonsurgical cardiovascular expert.

For the available invasive treatment options, Statnetic et al. (65) illustrated the possible impact of a heart team approach in today's practice. The authors used the validated SYNTAX II score and applied it to 651 consecutive patients with triple-vessel CAD from a hospital without cardiac surgery onsite. The authors compared actual outcomes based on the selected treatment (CABG or PCI) to the suggested treatment recommendation based on the SYNTAX II score. The authors found that one-third of the patients were referred for CABG and two-thirds received PCI. According to SYNTAX II score, only 4 of the CABG patients (1.65%) would have received a primary PCI recommendation, whereas 35% ($n = 144$) of the PCI patients would have received a primary recommendation for CABG. Comparing mortality rates in the PCI patients, the highest mortality rate (12.5%) was found in those patients who had a primary recommendation



for CABG according to SYNTAX II. Mortality for those patients treated consistent with SYNTAX II score recommendations was significantly lower (6.9% PCI or CABG, and 0% only PCI). The authors calculated that adherence to the SYNTAX II score recommendations could have reduced actual mortality by 5.6% with a number needed to treat of 18. They discuss that U.S. compliance rates with guidelines for CAD treatment are only 53%. (65).

IMPACT OF “SURGICAL COLLATERALIZATION” ON CURRENT PRACTICE.

The aforementioned evidence piece by piece suggests that CABG provides “a collateralization effect” over revascularization by bypassing diseased territories and preventing symptoms in case of plaque rupture and vessel occlusion. Only the revascularization part may be comparable to PCI. It may be sobering to note that we continue to choose PCI over CABG in the “real world” management of stable CAD, despite the robust scientific evidence in support of CABG and the current clinical practice guidelines (1). Although the realization of mechanistic differences, as illustrated here, may require time, treatment decisions in real life may, however, be influenced by other factors than the extent of CAD. Advanced age and comorbidities may increase operative risk, and the need for symptomatic control may overcome a potential long-term benefit. Whether these reasons are always responsible is beyond this review, but they underscore the need for individual decision-making by a group of experts (heart team). In light of this discussion, several things may require revision for daily practice.

First and foremost, the terminology needs to change. CABG should no longer be considered a method of revascularization alone. It adds a mechanism of myocardial protection that explains its ability to prolong life (which may be less detectable if the disease is not associated with greater natural risk). Consenting patients, which is already suboptimal if it comes to addressing CABG as a revascularization option for CAD treatment (66), needs to change. Patients

should be informed that they can be treated for their symptoms with PCI and that they can obtain revascularization plus protection against new infarction from CABG.

For the conduct of CABG, the role of complete versus incomplete revascularization needs to be revisited and the mechanisms for early graft failure would need to be studied in more detail. For the conduct of PCI, restenosis and stent thrombosis would need to be solved before less stenotic lesions can be addressed, hoping for an impact of elective PCI on new myocardial infarctions and possibly survival.

Our current practice, however, suggests that treatment decisions are not always consistent with the currently available evidence (65) and recommendations (1). One potential solution may have arrived with the noninvasive imaging of even severe coronary artery disease using CT, potentially including functional flow assessments (33,67), allowing the objective discussion of risk-benefit tradeoffs (68) for CABG or PCI, independent of the need for a potential second intervention.

CONCLUSIONS

Coronary bypass surgery appears to bypass diseased coronary vessel segments (creating “surgical collateralization”) in addition to revascularization, a condition that allows vessels to occlude without causing a lethal or nonlethal myocardial infarction. The mechanism of CABG is therefore different from that of PCI. This recognition has the potential to significantly alter our current routine of decision-making in patients with stable CAD.

ACKNOWLEDGMENT The authors thank Benjamin Gloy for expert technical assistance in preparing the figures and the manuscript.

ADDRESS FOR CORRESPONDENCE: Prof. Torsten Doenst, Department of Cardiothoracic Surgery, Friedrich-Schiller-University of Jena, Am Klinikum 1, 07747 Jena, Germany. E-mail: doenst@med.uni-jena.de.

REFERENCES

1. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87–165.
2. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551–67.
3. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol* 2005;46:575–81.
4. Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. *N Engl J Med* 2015;372:1204–12.
5. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010;55:432–40.
6. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med* 2016;375:2223–35.
7. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;367:2375–84.
8. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical

trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* 2007;115:1082–9.

9. Makikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet* 2016;388:2743–52.

10. Ahn JM, Roh JH, Kim YH, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-year outcomes of the PRECOMBAT study. *J Am Coll Cardiol* 2015;65:2198–206.

11. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet* 2002;360:965–70.

12. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360:961–72.

13. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. *Eur Heart J* 2011;32:2125–34.

14. Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. Percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. *Eur Heart J* 2014;35:2821–30.

15. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. *JAMA Intern Med* 2014;174:223–30.

16. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. *JAMA Intern Med* 2014;174:232–40.

17. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med* 2005;352:2174–83.

18. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med* 2008;358:331–41.

19. Katz MH. Evolving treatment options in coronary artery disease. *JAMA Intern Med* 2014;174:231.

20. Rodriguez AE, Fernandez-Pereira C, Mieres J. Coronary artery bypass grafting vs percutaneous coronary intervention in multivessel disease. *JAMA Intern Med* 2014;174:1007.

21. Takagi H, Umemoto T. Coronary artery bypass grafting vs percutaneous coronary intervention in

multivessel disease. *JAMA Intern Med* 2014;174:1006–7.

22. Boden WE, Taggart DP. Diabetes with coronary disease—a moving target amid evolving therapies? *N Engl J Med* 2009;360:2570–2.

23. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360:2503–15.

24. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995;92:657–71.

25. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? *Circulation* 1988;78:1157–66.

26. Alderman EL, Corley SD, Fisher LD, et al., CASS Participating Investigators and Staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). *J Am Coll Cardiol* 1993;22:1141–54.

27. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. *J Am Coll Cardiol* 1988;12:56–62.

28. Giroud D, Li JM, Urban P, Meier B, Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. *Am J Cardiol* 1992;69:729–32.

29. Habib RH, Dimitrova KR, Badour SA, et al. CABG versus PCI: greater benefit in long-term outcomes with multiple arterial bypass grafting. *J Am Coll Cardiol* 2015;66:1417–27.

30. Kumada Y, Ishii H, Aoyama T, et al. Long-term clinical outcome after surgical or percutaneous coronary revascularization in hemodialysis patients. *Circ J* 2014;78:986–92.

31. Nam CW, Mangiacapra F, Entjes R, et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. *J Am Coll Cardiol* 2011;58:1211–8.

32. Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? *J Am Coll Cardiol* 1991;18:904–10.

33. Norgaard BL, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). *J Am Coll Cardiol* 2014;63:1145–55.

34. Pellicano M, De Bruyne B, Toth GG, Casselman F, Wijns W, Barbato E. Fractional flow reserve to guide and to assess coronary artery bypass grafting. *Eur Heart J* 2017;38:1959–68.

35. Petrie MC, Jhund PS, She L, et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). *Circulation* 2016;134:1314–24.

36. Roberts JK, Rao SV, Shaw LK, Gallup DS, Marroquin OC, Patel UD. Comparative efficacy of coronary revascularization procedures for multivessel coronary artery disease in patients with chronic kidney disease. *Am J Cardiol* 2017;119:1344–51.

37. Serruys PW, Katagiri Y, Sotomi Y, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. *J Am Coll Cardiol* 2017;70:60–74.

38. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 2009;360:213–24.

39. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2012;367:991–1001.

40. Milojevic M, Head SJ, Parasca CA, et al. Causes of death following PCI Versus CABG in complex CAD: 5-year follow-up of SYNTAX. *J Am Coll Cardiol* 2016;67:42–55.

41. Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet* 2018;391:939–48.

42. Jeon C, Candia SC, Wang JC, et al. Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction. *Am Heart J* 2010;160:195–201.

43. Von Reutern G-M. Measuring the degree of internal carotid artery stenosis. *Perspect Med* 2012;1:104–7.

44. Toth GG, Toth B, Johnson NP, et al. Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy. *Circ Cardiovasc Interv* 2014;7:751–9.

45. Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. *Eur Heart J* 2013;34:2674–82.

46. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. *Circulation* 2004;110:278–84.

47. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011;364:1607–16.

48. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016;374:1511–20.

49. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ* 2014;348:g3859.

50. Bona KH, Mannsverk J, Wiseth R, et al. Drug-eluting or bare-metal stents for coronary artery disease. *N Engl J Med* 2016;375:1242–52.

51. Plass CA, Sabyusheva-Litschauer I, Bernhart A, et al. Time course of endothelium-dependent and -independent coronary vasomotor response to coronary balloons and stents.

- Comparison of plain and drug-eluting balloons and stents. *J Am Coll Cardiol Interv* 2012;5:741-51.
52. Thielmann M, Leyh R, Massoudy P, et al. Prognostic significance of multiple previous percutaneous coronary interventions in patients undergoing elective coronary artery bypass surgery. *Circulation* 2006;114:l441-7.
 53. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med* 2011;364:1617-25.
 54. Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. *J Am Coll Cardiol* 2013;61:1860-70.
 55. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation* 2003;107:2900-7.
 56. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. Medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *Eur Heart J* 2011;32:1012-24.
 57. Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med* 2018;379:924-33.
 58. Mushtaq S, De Araujo Goncalves P, Garcia-Garcia HM, et al. Long-term prognostic effect of coronary atherosclerotic burden: validation of the computed tomography-Leaman score. *Circ Cardiovasc Imag* 2015;8:e002332.
 59. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. *N Engl J Med* 2015;372:1213-22.
 60. Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. *J Am Coll Cardiol* 2017;70:2852-62.
 61. Chernyavskiy A, Volkov A, Lavrenyuk O, Terekhov I, Kareva Y. Comparative results of endoscopic and open methods of vein harvesting for coronary artery bypass grafting: a prospective randomized parallel-group trial. *J Cardiothorac Surg* 2015;10:163.
 62. Robinson BM, Paterson HS, Naidoo R, Dhurandhar V, Denniss AR. Bilateral internal thoracic artery composite Y grafts: analysis of 464 angiograms in 296 patients. *Ann Thorac Surg* 2016;101:974-80.
 63. Fournier S, Toth GG, De Bruyne B, et al. Six-year follow-up of fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. *Circ Cardiovasc Interv* 2018;11:e006368.
 64. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;34:2949-3003.
 65. Stanetic BM, Ostojic M, Campos CM, et al. Appropriateness of myocardial revascularization assessed by the SYNTAX score II in a country without cardiac surgery facilities; PROUST study. *Int J Cardiol* 2017;227:478-84.
 66. Chandrasekharan DP, Taggart DP. Informed consent for interventions in stable coronary artery disease: problems, etiologies, and solutions. *Eur J Cardiothorac Surg* 2011;39:912-7.
 67. Collet C, Onuma Y, Andreini D, et al. Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. *Eur Heart J* 2018;39:3689-98.
 68. Federspiel JJ, Stearns SC, van Domburg RT, Sheridan BC, Lund JL, Serruys PW. Risk-benefit trade-offs in revascularisation choices. *Euro-intervention* 2011;6:936-41.
 69. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2014;64:1929-49.

KEY WORDS heart team, prognosis, survival benefit